Targeted Therapies in Pheochromocytoma and Paraganglioma
Abstract Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use,...
Saved in:
| Published in | The journal of clinical endocrinology and metabolism Vol. 107; no. 11; pp. 2963 - 2972 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
US
Oxford University Press
01.11.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0021-972X 1945-7197 1945-7197 |
| DOI | 10.1210/clinem/dgac471 |
Cover
| Abstract | Abstract
Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2α inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. |
|---|---|
| AbstractList | Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2α inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/
VHL/EPAS1
-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/
SDHx
-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2a] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2a inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. Key Words: molecular targeted therapy, metastatic, pheochromocytoma, paraganglioma Abbreviations: ccRCC, clear cell renal cell carcinoma; CT, computed tomography; CVD, cyclophosphamide/vincristine/dacarbazine; DCR, disease control rate; FDA, US Food and Drug Administration; [[.sup.18]F]-FDOPA PET/CT, [[.sup.18]F]-fluorodihydroxyphenylalanine positron emission tomography-CT; HIF2a, hypoxiainducible factor 2 alpha; HSA, high specific activity; MRI, magnetic resonance imaging; NET, neuroendocrine tumor; ORR, objective response rate; PARP, poly (ADP-ribose) polymerase; PFS, progression-free survival; PPGL, pheochromocytoma and paraganglioma; PRRT, peptide (somatostatin) receptor (SSTR)-based radionuclide therapy; RCC, renal cell carcinoma; SSTR, somatostatin receptor; TKI, tyrosine kinase inhibitor; VHL, von Hippel-Lindau; [[.sup.68]Ga]DOTA-SSA PET/CT, [.sup.68]Gallium-labeled somatostatin analogue positron emission tomography-computed tomography Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2 alpha] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2 alpha inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2α inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2a] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2a inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2α inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes.Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2α inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. Abstract Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare tumors but remain difficult to treat. This mini-review provides an overview of established molecular targeted therapies in present use, and perspectives on those currently under development and evaluation in clinical trials. Recently published research articles, guidelines, and expert views on molecular targeted therapies in PPGLs are systematically reviewed and summarized. Some tyrosine kinase inhibitors (sunitinib, cabozantinib) are already in clinical use with some promising results, but without formal approval for the treatment of PPGLs. Sunitinib is the only therapeutic option which has been investigated in a randomized placebo-controlled clinical trial. It is clinically used as a first-, second-, or third-line therapeutic option for the treatment of progressive metastatic PPGLs. Some other promising molecular targeted therapies (hypoxia-inducible factor 2 alpha [HIF2α] inhibitors, tumor vaccination together with checkpoint inhibitors, antiangiogenic therapies, kinase signaling inhibitors) are under evaluation in clinical trials. The HIF2α inhibitor belzutifan may prove to be particularly interesting for cluster 1B-/VHL/EPAS1-related PPGLs, whereas antiangiogenic therapies seem to be primarily effective in cluster 1A-/SDHx-related PPGLs. Some combination therapies currently being evaluated in clinical trials, such as temozolomide/olaparib, temozolomide/talazoparib, or cabozantinib/atezolizumab, will provide data for novel therapy for metastatic PPGLs. It is likely that advances in such molecular targeted therapies will play an essential role in the future treatment of these tumors, with more personalized therapy options paving the way towards improved therapeutic outcomes. |
| Audience | Academic |
| Author | Wang, Katharina Nölting, Svenja Crona, Joakim Beuschlein, Felix Pacak, Karel Grossman, Ashley B |
| Author_xml | – sequence: 1 givenname: Katharina orcidid: 0000-0002-7795-1395 surname: Wang fullname: Wang, Katharina – sequence: 2 givenname: Joakim surname: Crona fullname: Crona, Joakim – sequence: 3 givenname: Felix orcidid: 0000-0001-7826-3984 surname: Beuschlein fullname: Beuschlein, Felix – sequence: 4 givenname: Ashley B orcidid: 0000-0003-1176-6186 surname: Grossman fullname: Grossman, Ashley B – sequence: 5 givenname: Karel orcidid: 0000-0002-3541-3767 surname: Pacak fullname: Pacak, Karel – sequence: 6 givenname: Svenja orcidid: 0000-0002-7064-590X surname: Nölting fullname: Nölting, Svenja email: svenja.noelting@usz.ch |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35973976$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-497517$$DView record from Swedish Publication Index |
| BookMark | eNqFkttrFDEUxoNU7Lb66qMM-KLgtLlOJi_CUq9QsA-r-BYymTOzKTPJNplR-t-bZdfWLYrkIXDO7_sO53KCjnzwgNBzgs8IJfjcDs7DeN72xnJJHqEFUVyUkih5hBYYU1IqSb8fo5OUrjEmnAv2BB0zoSRTslqgemViDxO0xWoN0WwcpML54moNwa5jGIO9ncJoCuPb4spE0xvfDy5HnqLHnRkSPNv_p-jrh_eri0_l5ZePny-Wl6UVNZ1KAk1TA5ON5W3XVFJJ1UhLRV2LWlUCRCtAtdZQa03HKwCLVQesMR0Ipgxjp-jNzjf9hM3c6E10o4m3Ohin37lvSx1ir-dZcyUFkRl_u8MzO0JrwU_RDAeqw4x3a92HH1opympMs8GrvUEMNzOkSY8uWRgG4yHMSVOJGSeSqi368gF6Hebo8zQ0IxXnSkjF7qneDKCd70Kua7emeimlFLXkFc_U2V-o_FoYnc0771yOHwhe_NnoXYe_V3vvaGNIKUJ3hxCst7ejd7ej97eTBfyBwLrJTC5sB-WGf8te72Rh3vyvxC9Latma |
| CitedBy_id | crossref_primary_10_1016_j_beem_2024_101954 crossref_primary_10_1111_jne_70017 crossref_primary_10_1530_ERC_22_0217 crossref_primary_10_1297_cpe_2024_0020 crossref_primary_10_3389_fendo_2023_1137456 crossref_primary_10_1007_s11864_024_01288_z crossref_primary_10_1016_j_mpaic_2023_07_003 crossref_primary_10_1016_j_cpt_2023_05_003 crossref_primary_10_1210_jendso_bvae061 crossref_primary_10_3390_ijms252312762 crossref_primary_10_1210_clinem_dgad311 crossref_primary_10_1097_RLU_0000000000004870 crossref_primary_10_1111_cen_15070 crossref_primary_10_1016_j_clgc_2023_12_012 crossref_primary_10_37349_etat_2024_00222 crossref_primary_10_1210_clinem_dgae241 crossref_primary_10_37349_eemd_2024_00018 crossref_primary_10_1210_clinem_dgae283 crossref_primary_10_3389_fendo_2023_1167796 crossref_primary_10_3389_fonc_2022_1045517 crossref_primary_10_1136_jcp_2023_209234 crossref_primary_10_1016_j_ejca_2024_114122 crossref_primary_10_3390_ph17030354 crossref_primary_10_3390_cancers16122191 crossref_primary_10_1016_j_plabm_2024_e00358 crossref_primary_10_26442_00403660_2024_07_202779 crossref_primary_10_3389_fendo_2023_1274239 crossref_primary_10_3389_fendo_2024_1433582 crossref_primary_10_1016_j_eucr_2024_102842 crossref_primary_10_1186_s13550_024_01168_5 crossref_primary_10_7759_cureus_75659 crossref_primary_10_17925_EE_2023_19_2_11 crossref_primary_10_1210_clinem_dgad166 crossref_primary_10_3390_cancers16030584 crossref_primary_10_1093_ejendo_lvad146 crossref_primary_10_1016_j_anl_2024_01_007 crossref_primary_10_1210_jendso_bvae092 |
| Cites_doi | 10.1016/S1470-2045(15)00290-9 10.1016/j.ccell.2017.01.001 10.1210/en.2019-00410 10.1111/bcpt.12313 10.1007/s00259-019-04567-2 10.1053/ejso.2002.1413 10.1200/JCO.2021.39.6_suppl.272 10.1530/ERC-11-0243 10.4158/EP15725.OR 10.1210/jc.2018-01968 10.3390/cancers11101505 10.3389/fendo.2018.00277 10.1210/jc.2014-1498 10.1073/pnas.0907843106 10.1530/ERC-16-0479 10.1530/eje.0.1410619 10.1097/SLA.0000000000002195 10.1007/s40265-021-01606-x 10.1016/j.trecan.2017.11.001 10.1016/annonc/annonc700 10.1093/hmg/ddr324 10.3390/cancers14030594 10.1210/jc.2017-00992 10.3389/fendo.2020.586857 10.1016/S0140-6736(05)67139-5 10.1507/endocrj.50.507 10.1136/jitc-2019-000347 10.1186/s12885-020-07568-9 10.1056/NEJMoa2026982 10.1055/s-0029-1220687 10.1002/onco.13770 10.1016/j.ejphar.2018.07.034 10.3390/cancers12020345 10.1210/jc.2010-1899 10.1002/jbmr.3860 10.1245/s10434-020-08220-3 10.1111/cen.13434 10.3390/cancers11060809 10.1038/s41574-021-00492-3 10.1056/NEJMoa2005651 10.1159/000348584 10.1210/endrev/bnab019 10.1530/EC-21-0455 10.1016/S0140-6736(15)00817-X 10.1158/1541-7786.MCR-20-0992 10.1097/MPA.0000000000001792 10.1186/1471-2407-14-523 10.1210/jc.2017-00816 10.1002/cncr.27675 10.1056/NEJMoa1316158 10.2967/jnumed.118.217463 10.1515/cclm-2020-0904 10.1158/1078-0432.CCR-17-3406 10.1007/BF00353738 10.1007/s00259-019-04398-1 10.1016/j.esmoop.2021.100233 10.1200/JCO.2005.03.6046 10.3390/cancers12082307 10.1080/02841860701441848 10.1007/s13139-019-00629-3 10.1056/NEJMoa1009290 10.2967/jnumed.114.138834 10.1056/NEJMoa2035716 10.3389/fendo.2020.594264 10.1111/cen.12542 10.1097/00000658-199906000-00001 10.1038/s41416-019-0474-x 10.1016/j.adro.2017.11.002 10.1530/ERC-19-0024 10.1016/j.ejca.2011.07.016 10.1210/jc.2006-0423 10.1055/a-0851-3275 10.1200/PO.21.00127 10.1634/theoncologist.2014-0328 10.1056/NEJMoa2103425 10.1200/JCO.2009.22.8510 10.1002/ijc.28913 10.1007/s12022-011-9189-0 10.1245/s10434-016-5739-5 10.7326/0003-4819-134-4-200102200-00016 10.1155/2015/138573 10.1200/JCO.2010.33.7873 10.1007/s12020-017-1359-5 10.2967/jnumed.112.102764 10.1002/hed.23348 10.1210/jc.2004-1398 10.1210/jc.2018-02411 10.1097/00000658-197405000-00029 10.1530/ERC-20-0043 10.1530/ERC-20-0205 10.1200/jco.2015.33.7_suppl.457 10.3390/cancers11020195 10.1097/HJH.0000000000002438 10.1200/JCO.20.02903 10.1530/ERC-21-0355 10.1210/jendso/bvac044 10.1177/1179554918763367 10.1210/clinem/dgaa502 10.1210/jc.2012-2356 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022 The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. COPYRIGHT 2022 Oxford University Press The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. – notice: COPYRIGHT 2022 Oxford University Press – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 5PM ADTPV AOWAS DF2 |
| DOI | 10.1210/clinem/dgac471 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Uppsala universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1945-7197 |
| EndPage | 2972 |
| ExternalDocumentID | oai_DiVA_org_uu_497517 PMC9923802 A777587464 35973976 10_1210_clinem_dgac471 10.1210/clinem/dgac471 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: DFG grantid: 314061271 -TRR 205 – fundername: University Medicine Zurich – fundername: ; – fundername: ; grantid: 314061271 –TRR 205 |
| GroupedDBID | --- -~X .55 .GJ .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 3O- 3V. 4.4 48X 53G 5GY 5RS 5YH 7X7 88E 8F7 8FI 8FJ AABZA AACZT AAIMJ AAJQQ AAKAS AAPGJ AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL AAYJJ ABBLC ABDFA ABDPE ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABUWG ABVGC ABWST ABXVV ACFRR ACGFO ACGFS ACPRK ACUTJ ACYHN ACZBC ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK ADZCM AELWJ AEMDU AENEX AENZO AERZD AETBJ AEWNT AFCHL AFFNX AFFQV AFFZL AFGWE AFKRA AFOFC AFRAH AFXAL AFYAG AGINJ AGKRT AGMDO AGQXC AGUTN AHMBA AHMMS AI. AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT APJGH AQDSO AQKUS ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BSWAC BTRTY BVXVI C45 CCPQU CDBKE CS3 D-I DAKXR DIK E3Z EBS EIHJH EJD EMOBN ENERS F5P FECEO FEDTE FHSFR FLUFQ FOEOM FOTVD FQBLK FYUFA GAUVT GJXCC GX1 H13 HMCUK HVGLF HZ~ H~9 IAO IHR INH ITC J5H KBUDW KOP KQ8 KSI KSN L7B M1P M5~ MBLQV MHKGH MJL N4W N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G PQQKQ PROAC PSQYO REU ROX ROZ TEORI TJX TLC TMA TR2 TWZ UKHRP VH1 VVN W8F WHG WOQ X52 X7M YBU YFH YHG YOC YSK ZGI ZXP ZY1 ~02 ~H1 AAYXX ABXZS ADNBA AEMQT AEOTA AGORE AHGBF AJBYB ALXQX CITATION NU- CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM AEHZK H94 K9. 7X8 5PM ACVCV ADMTO ADTPV AJDVS AOWAS AVNTJ DF2 OBFPC PHGZM PHGZT PJZUB PPXIY PUEGO |
| ID | FETCH-LOGICAL-c582t-1ebb8e37bc4dfb67979b7c258858965e5d5e9dca2ccaf46eec09fe3bafe539a33 |
| ISSN | 0021-972X 1945-7197 |
| IngestDate | Tue Sep 09 23:23:00 EDT 2025 Thu Aug 21 18:40:38 EDT 2025 Mon Sep 08 07:35:55 EDT 2025 Fri Sep 19 20:52:51 EDT 2025 Tue Jun 17 22:23:58 EDT 2025 Tue Jun 10 21:20:21 EDT 2025 Thu Apr 03 07:00:18 EDT 2025 Tue Jul 01 01:11:08 EDT 2025 Thu Apr 24 23:08:51 EDT 2025 Fri Feb 07 10:35:40 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | pheochromocytoma molecular targeted therapy metastatic paraganglioma |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights) https://academic.oup.com/pages/standard-publication-reuse-rights The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c582t-1ebb8e37bc4dfb67979b7c258858965e5d5e9dca2ccaf46eec09fe3bafe539a33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0003-1176-6186 0000-0002-3541-3767 0000-0002-7064-590X 0000-0002-7795-1395 0000-0001-7826-3984 |
| PMID | 35973976 |
| PQID | 3164495793 |
| PQPubID | 2046206 |
| PageCount | 10 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_uu_497517 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9923802 proquest_miscellaneous_2703417292 proquest_journals_3164495793 gale_infotracmisc_A777587464 gale_infotracacademiconefile_A777587464 pubmed_primary_35973976 crossref_primary_10_1210_clinem_dgac471 crossref_citationtrail_10_1210_clinem_dgac471 oup_primary_10_1210_clinem_dgac471 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-01 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Washington |
| PublicationTitle | The journal of clinical endocrinology and metabolism |
| PublicationTitleAlternate | J Clin Endocrinol Metab |
| PublicationYear | 2022 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Mweempwa (2023021311515739000_CIT0083) 2021; 5 Nölting (2023021311515739000_CIT0012) 2022; 43 Pryma (2023021311515739000_CIT0013) 2019; 60 Rosland (2023021311515739000_CIT0032) 2015; 116 Brouwers (2023021311515739000_CIT0022) 2006; 91 Fani (2023021311515739000_CIT0058) 2012; 53 Luchetti (2023021311515739000_CIT0004) 2015; 2015 Gieldon (2023021311515739000_CIT0005) 2019; 11 Roman-Gonzalez (2023021311515739000_CIT0043) 2018; 268 Fankhauser (2023021311515739000_CIT0087) 2019; 160 van Hulsteijn (2023021311515739000_CIT0101) 2013; 35 Hamidi (2023021311515739000_CIT0039) 2017; 102 Favier (2023021311515739000_CIT0061) 2012; 23 Fishbein (2023021311515739000_CIT0003) 2017; 31 Taieb (2023021311515739000_CIT0038) 2019; 46 Strajina (2023021311515739000_CIT0044) 2017; 24 Burotto Pichun (2023021311515739000_CIT0067) 2015; 33 Goldstein (2023021311515739000_CIT0018) 1999; 229 Eisenhofer (2023021311515739000_CIT0035) 2017; 38 Jochmanova (2023021311515739000_CIT0007) 2018; 4 Lee (2023021311515739000_CIT0031) 2018; 834 Amar (2023021311515739000_CIT0037) 2021; 17 Hescot (2023021311515739000_CIT0040) 2019; 104 Druce (2023021311515739000_CIT0080) 2009; 41 Amar (2023021311515739000_CIT0020) 2005; 90 Wirth (2023021311515739000_CIT0082) 2020; 383 Yao (2023021311515739000_CIT0086) 2016; 387 Peng (2023021311515739000_CIT0078) 2020; 11 Jonasch (2023021311515739000_CIT0076) 2021; 385 Wei (2023021311515739000_CIT0045) 2013; 9 Naing (2023021311515739000_CIT0071) 2020; 8 Fishbein (2023021311515739000_CIT0042) 2021; 50 Imhof (2023021311515739000_CIT0056) 2011; 29 Hadoux (2023021311515739000_CIT0049) 2014; 135 Ayala-Ramirez (2023021311515739000_CIT0064) 2012; 97 Niemeijer (2023021311515739000_CIT0048) 2014; 81 Tonyukuk (2023021311515739000_CIT0100) 2003; 50 Lenders (2023021311515739000_CIT0009) 2014; 99 Jasim (2023021311515739000_CIT0068) 2017; 57 Jimenez (2023021311515739000_CIT0066) 2017 Eisenhofer (2023021311515739000_CIT0036) 2020; 59 Wiele (2023021311515739000_CIT0089) 2021; 26 Remine (2023021311515739000_CIT0016) 1974; 179 Wild (2023021311515739000_CIT0059) 2014; 55 Wang (2023021311515739000_CIT0065) 2022 Kong (2023021311515739000_CIT0052) 2017; 102 Eisenhofer (2023021311515739000_CIT0014) 2012; 48 Tena (2023021311515739000_CIT0102) 2018; 12 Bechmann (2023021311515739000_CIT0024) 2020; 27 Jiang (2023021311515739000_CIT0006) 2020; 105 Kulke (2023021311515739000_CIT0050) 2006; 24 Jimenez (2023021311515739000_CIT0060) 2018; 9 Pacak (2023021311515739000_CIT0034) 2001; 134 Kohlenberg (2023021311515739000_CIT0096) 2019; 11 Economides (2023021311515739000_CIT0074) 2020; 11 Choueiri (2023021311515739000_CIT0073) 2021; 384 Motzer (2023021311515739000_CIT0072) 2021; 384 Proye (2023021311515739000_CIT0017) 1994; 18 Burnichon (2023021311515739000_CIT0008) 2011; 20 Jha (2023021311515739000_CIT0103) 2020; 54 Hong (2023021311515739000_CIT0091) 2011; 96 Oh (2023021311515739000_CIT0081) 2012; 118 Lenders (2023021311515739000_CIT0011) 2020; 38 Schovanek (2023021311515739000_CIT0023) 2014; 14 Hassan Nelson (2023021311515739000_CIT0069) 2022; 6 Jin (2023021311515739000_CIT0092) 2020; 12 Yao (2023021311515739000_CIT0085) 2011; 364 Baudin (2023021311515739000_CIT0047) 2021; 32 Turkova (2023021311515739000_CIT0028) 2016; 22 Ziegler (2023021311515739000_CIT0054) 2009; 106 Fonte (2023021311515739000_CIT0053) 2012; 19 Jimenez (2023021311515739000_CIT0070) 2020; 12 Edstrom Elder (2023021311515739000_CIT0021) 2003; 29 Arnas-Leon (2023021311515739000_CIT0046) 2016; 8 Wang (2023021311515739000_CIT0095) 2020; 20 Crona (2023021311515739000_CIT0002) 2019; 26 Motzer (2023021311515739000_CIT0088) 2015; 16 Reid (2023021311515739000_CIT0094) 2020; 35 O’Kane (2023021311515739000_CIT0063) 2019; 120 Toledo (2023021311515739000_CIT0077) 2017; 24 Breen (2023021311515739000_CIT0097) 2018; 3 Nölting (2023021311515739000_CIT0030) 2018; 127 Jhawar (2023021311515739000_CIT0001) 2022; 14 Ho (2023021311515739000_CIT0084) 2021; 39 Deeks (2023021311515739000_CIT0075) 2021; 81 Buffet (2023021311515739000_CIT0010) 2019; 104 Mei (2023021311515739000_CIT0041) 2019; 51 Jimenez (2023021311515739000_CIT0062) 2020; 27 Alzofon (2023021311515739000_CIT0026) 2021 Lenders (2023021311515739000_CIT0033) 2005; 366 Waqar (2023021311515739000_CIT0090) 2013; 59 Choueiri (2023021311515739000_CIT0079) 2021; 39 Wang (2023021311515739000_CIT0093) 2015; 20 Rinke (2023021311515739000_CIT0099) 2009; 27 Heregger (2023021311515739000_CIT0104) 2021; 6 Hamidi (2023021311515739000_CIT0027) 2017; 87 Patel (2023021311515739000_CIT0015) 2020; 27 Mannelli (2023021311515739000_CIT0019) 1999; 141 Nölting (2023021311515739000_CIT0029) 2019; 11 Caplin (2023021311515739000_CIT0098) 2014; 371 Van Essen (2023021311515739000_CIT0055) 2007; 46 Ballal (2023021311515739000_CIT0057) 2020; 47 Pang (2023021311515739000_CIT0051) 2018; 24 Kumar (2023021311515739000_CIT0025) 2021; 10 |
| References_xml | – volume: 16 start-page: 1473 issue: 15 year: 2015 ident: 2023021311515739000_CIT0088 article-title: Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(15)00290-9 – volume: 31 start-page: 181 issue: 2 year: 2017 ident: 2023021311515739000_CIT0003 article-title: Comprehensive molecular characterization of pheochromocytoma and paraganglioma publication-title: Cancer Cell doi: 10.1016/j.ccell.2017.01.001 – volume: 160 start-page: 2600 issue: 11 year: 2019 ident: 2023021311515739000_CIT0087 article-title: Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures publication-title: Endocrinology doi: 10.1210/en.2019-00410 – volume: 116 start-page: 9 issue: 1 year: 2015 ident: 2023021311515739000_CIT0032 article-title: Novel points of attack for targeted cancer therapy publication-title: Basic Clin Pharmacol Toxicol. doi: 10.1111/bcpt.12313 – volume: 47 start-page: 934 issue: 4 year: 2020 ident: 2023021311515739000_CIT0057 article-title: Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety publication-title: Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-019-04567-2 – volume: 29 start-page: 278 issue: 3 year: 2003 ident: 2023021311515739000_CIT0021 article-title: The management of benign and malignant pheochromocytoma and abdominal paraganglioma publication-title: Eur J Surg Oncol. doi: 10.1053/ejso.2002.1413 – volume: 39 start-page: 272 issue: 6_suppl year: 2021 ident: 2023021311515739000_CIT0079 article-title: Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC) publication-title: J Clin Oncol. doi: 10.1200/JCO.2021.39.6_suppl.272 – volume: 9 start-page: S183 issue: Suppl year: 2013 ident: 2023021311515739000_CIT0045 article-title: Surgical resection of multiple liver metastasis of functional malignant pheochromocytoma: a case report and literature review publication-title: J Cancer Res Ther. – volume: 19 start-page: 83 issue: 1 year: 2012 ident: 2023021311515739000_CIT0053 article-title: False-negative (1)(2)(3)I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-11-0243 – volume: 22 start-page: 302 issue: 3 year: 2016 ident: 2023021311515739000_CIT0028 article-title: Characteristics and outcomes of metastatic sdhb and sporadic pheochromocytoma/paraganglioma: an National Institutes of Health Study publication-title: Endocr Pract. doi: 10.4158/EP15725.OR – volume: 104 start-page: 2367 issue: 6 year: 2019 ident: 2023021311515739000_CIT0040 article-title: Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): a European Network for the study of adrenal tumors retrospective study publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-01968 – volume: 11 issue: 10 year: 2019 ident: 2023021311515739000_CIT0029 article-title: Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine publication-title: Cancers doi: 10.3390/cancers11101505 – volume: 9 start-page: 277 year: 2018 ident: 2023021311515739000_CIT0060 article-title: Treatment for patients with malignant pheochromocytomas and paragangliomas: a perspective from the hallmarks of cancer publication-title: Front Endocrinol doi: 10.3389/fendo.2018.00277 – volume: 99 start-page: 1915 issue: 6 year: 2014 ident: 2023021311515739000_CIT0009 article-title: Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2014-1498 – volume: 106 start-page: 15879 issue: 37 year: 2009 ident: 2023021311515739000_CIT0054 article-title: Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues publication-title: Proc Natl Acad Sci USA. doi: 10.1073/pnas.0907843106 – volume: 24 start-page: C9 issue: 9 year: 2017 ident: 2023021311515739000_CIT0077 article-title: New HIF2alpha inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas publication-title: Endocr Relat Cancer doi: 10.1530/ERC-16-0479 – volume: 141 start-page: 619 issue: 6 year: 1999 ident: 2023021311515739000_CIT0019 article-title: Pheochromocytoma in Italy: a multicentric retrospective study publication-title: Eur J Endocrinol. doi: 10.1530/eje.0.1410619 – volume: 268 start-page: 172 issue: 1 year: 2018 ident: 2023021311515739000_CIT0043 article-title: Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma publication-title: Ann Surg. doi: 10.1097/SLA.0000000000002195 – volume: 81 start-page: 1921 issue: 16 year: 2021 ident: 2023021311515739000_CIT0075 article-title: Belzutifan: first approval publication-title: Drugs. doi: 10.1007/s40265-021-01606-x – volume: 4 start-page: 6 issue: 1 year: 2018 ident: 2023021311515739000_CIT0007 article-title: Genomic landscape of pheochromocytoma and paraganglioma publication-title: Trends Cancer doi: 10.1016/j.trecan.2017.11.001 – volume: 32 start-page: S621 year: 2021 ident: 2023021311515739000_CIT0047 article-title: First International Randomized Study in Malignant Progressive Pheochromocytoma and Paragangliomas (FIRSTMAPPP): an academic double-blind trial investigating sunitinib publication-title: Ann Oncol. doi: 10.1016/annonc/annonc700 – volume: 20 start-page: 3974 issue: 20 year: 2011 ident: 2023021311515739000_CIT0008 article-title: Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma publication-title: Hum Mol Genet. doi: 10.1093/hmg/ddr324 – volume: 14 issue: 3 year: 2022 ident: 2023021311515739000_CIT0001 article-title: New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications publication-title: Cancers doi: 10.3390/cancers14030594 – volume: 102 start-page: 3296 issue: 9 year: 2017 ident: 2023021311515739000_CIT0039 article-title: Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2017-00992 – volume: 11 start-page: 586857 year: 2020 ident: 2023021311515739000_CIT0078 article-title: The VHL/HIF axis in the development and treatment of pheochromocytoma/paraganglioma publication-title: Front Endocrinol doi: 10.3389/fendo.2020.586857 – volume: 366 start-page: 665 issue: 9486 year: 2005 ident: 2023021311515739000_CIT0033 article-title: Phaeochromocytoma publication-title: Lancet doi: 10.1016/S0140-6736(05)67139-5 – volume: 50 start-page: 507 issue: 5 year: 2003 ident: 2023021311515739000_CIT0100 article-title: Case report: patient with multiple paragangliomas treated with long acting somatostatin analogue publication-title: Endocr J. doi: 10.1507/endocrj.50.507 – volume: 8 issue: 1 year: 2020 ident: 2023021311515739000_CIT0071 article-title: Phase 2 study of pembrolizumab in patients with advanced rare cancers publication-title: J ImmunoTher Cancer. doi: 10.1136/jitc-2019-000347 – volume: 20 start-page: 1059 issue: 1 year: 2020 ident: 2023021311515739000_CIT0095 article-title: Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review publication-title: BMC Cancer doi: 10.1186/s12885-020-07568-9 – volume: 384 start-page: 829 issue: 9 year: 2021 ident: 2023021311515739000_CIT0073 article-title: Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma publication-title: N Engl J Med. doi: 10.1056/NEJMoa2026982 – volume: 41 start-page: 697 issue: 9 year: 2009 ident: 2023021311515739000_CIT0080 article-title: Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) publication-title: Horm Metab Res. doi: 10.1055/s-0029-1220687 – volume: 26 start-page: 476 issue: 6 year: 2021 ident: 2023021311515739000_CIT0089 article-title: Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies publication-title: Oncologist doi: 10.1002/onco.13770 – volume: 834 start-page: 188 year: 2018 ident: 2023021311515739000_CIT0031 article-title: Molecular targeted therapy: treating cancer with specificity publication-title: Eur J Pharmacol. doi: 10.1016/j.ejphar.2018.07.034 – volume: 12 issue: 2 year: 2020 ident: 2023021311515739000_CIT0092 article-title: Inhibition of Wnt/beta-catenin signaling in neuroendocrine tumors in vitro: antitumoral effects publication-title: Cancers doi: 10.3390/cancers12020345 – volume: 96 start-page: 997 issue: 4 year: 2011 ident: 2023021311515739000_CIT0091 article-title: Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2010-1899 – volume: 35 start-page: 20 issue: 1 year: 2020 ident: 2023021311515739000_CIT0094 article-title: Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women publication-title: J Bone Miner Res. doi: 10.1002/jbmr.3860 – volume: 27 start-page: 1329 issue: 5 year: 2020 ident: 2023021311515739000_CIT0015 article-title: Update on pheochromocytoma and paraganglioma from the SSO Endocrine/Head and Neck Disease-Site Work Group. Part 1 of 2: advances in pathogenesis and diagnosis of pheochromocytoma and paraganglioma publication-title: Ann Surg Oncol. doi: 10.1245/s10434-020-08220-3 – volume: 87 start-page: 440 issue: 5 year: 2017 ident: 2023021311515739000_CIT0027 article-title: Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis publication-title: Clin Endocrinol doi: 10.1111/cen.13434 – volume: 11 issue: 6 year: 2019 ident: 2023021311515739000_CIT0005 article-title: Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches publication-title: Cancers doi: 10.3390/cancers11060809 – volume: 17 start-page: 435 issue: 7 year: 2021 ident: 2023021311515739000_CIT0037 article-title: International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers publication-title: Nat Rev Endocrinol. doi: 10.1038/s41574-021-00492-3 – volume: 383 start-page: 825 issue: 9 year: 2020 ident: 2023021311515739000_CIT0082 article-title: Efficacy of selpercatinib in RET-altered thyroid cancers publication-title: N Engl J Med. doi: 10.1056/NEJMoa2005651 – volume: 59 start-page: 8 issue: 1 year: 2013 ident: 2023021311515739000_CIT0090 article-title: A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer publication-title: Chemotherapy doi: 10.1159/000348584 – volume: 43 start-page: 199 issue: 2 year: 2022 ident: 2023021311515739000_CIT0012 article-title: Personalized management of pheochromocytoma and paraganglioma publication-title: Endocr Rev. doi: 10.1210/endrev/bnab019 – volume: 10 start-page: 1463 issue: 11 year: 2021 ident: 2023021311515739000_CIT0025 article-title: Metastatic cluster 2-related pheochromocytoma/paraganglioma: a single-center experience and systematic review publication-title: Endocr Connect doi: 10.1530/EC-21-0455 – volume: 387 start-page: 968 issue: 10022 year: 2016 ident: 2023021311515739000_CIT0086 article-title: Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study publication-title: Lancet doi: 10.1016/S0140-6736(15)00817-X – year: 2021 ident: 2023021311515739000_CIT0026 article-title: Mastermind like transcriptional coactivator 3 (MAML3) drives neuroendocrine tumor progression publication-title: Mol Cancer Res. doi: 10.1158/1541-7786.MCR-20-0992 – volume: 50 start-page: 469 issue: 4 year: 2021 ident: 2023021311515739000_CIT0042 article-title: The North American Neuroendocrine Tumor Society Consensus Guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma publication-title: Pancreas doi: 10.1097/MPA.0000000000001792 – volume: 14 start-page: 523 year: 2014 ident: 2023021311515739000_CIT0023 article-title: The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study publication-title: BMC Cancer doi: 10.1186/1471-2407-14-523 – volume: 102 start-page: 3278 issue: 9 year: 2017 ident: 2023021311515739000_CIT0052 article-title: Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2017-00816 – volume: 118 start-page: 6162 issue: 24 year: 2012 ident: 2023021311515739000_CIT0081 article-title: Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas publication-title: Cancer doi: 10.1002/cncr.27675 – year: 2017 ident: 2023021311515739000_CIT0066 article-title: A phase 2 study to evaluate the effects of cabozantinib in patients with unresectable metastatic pheochromocytomas and paragangliomas – volume: 371 start-page: 224 issue: 3 year: 2014 ident: 2023021311515739000_CIT0098 article-title: Lanreotide in metastatic enteropancreatic neuroendocrine tumors publication-title: N Engl J Med. doi: 10.1056/NEJMoa1316158 – volume: 60 start-page: 623 issue: 5 year: 2019 ident: 2023021311515739000_CIT0013 article-title: Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma publication-title: J Nucl Med. doi: 10.2967/jnumed.118.217463 – volume: 59 start-page: 353 issue: 2 year: 2020 ident: 2023021311515739000_CIT0036 article-title: Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma publication-title: Clin Chem Lab Med. doi: 10.1515/cclm-2020-0904 – volume: 24 start-page: 3423 issue: 14 year: 2018 ident: 2023021311515739000_CIT0051 article-title: Targeting NAD(+)/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster i pheochromocytoma and paraganglioma publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-17-3406 – volume: 18 start-page: 467 issue: 4 year: 1994 ident: 2023021311515739000_CIT0017 article-title: “The” pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? publication-title: World J Surg. doi: 10.1007/BF00353738 – volume: 46 start-page: 2112 issue: 10 year: 2019 ident: 2023021311515739000_CIT0038 article-title: European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma publication-title: Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-019-04398-1 – volume: 6 start-page: 100233 issue: 4 year: 2021 ident: 2023021311515739000_CIT0104 article-title: Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature publication-title: ESMO Open doi: 10.1016/j.esmoop.2021.100233 – volume: 38 start-page: 69 issue: 2 year: 2017 ident: 2023021311515739000_CIT0035 article-title: Metabologenomics of phaeochromocytoma and paraganglioma: an integrated approach for personalised biochemical and genetic testing publication-title: Clin Biochem Rev – volume: 24 start-page: 401 issue: 3 year: 2006 ident: 2023021311515739000_CIT0050 article-title: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors publication-title: J Clin Oncol. doi: 10.1200/JCO.2005.03.6046 – volume: 12 issue: 8 year: 2020 ident: 2023021311515739000_CIT0070 article-title: Phase II clinical trial of pembrolizumab in patients with progressive metastatic pheochromocytomas and paragangliomas publication-title: Cancers doi: 10.3390/cancers12082307 – volume: 46 start-page: 723 issue: 6 year: 2007 ident: 2023021311515739000_CIT0055 article-title: Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours publication-title: Acta Oncol. doi: 10.1080/02841860701441848 – volume: 54 start-page: 48 issue: 1 year: 2020 ident: 2023021311515739000_CIT0103 article-title: Role of (68)Ga-DOTATATE PET/CT in a case of SDHB-related pterygopalatine fossa paraganglioma successfully controlled with octreotide publication-title: Nucl Med Mol Imaging doi: 10.1007/s13139-019-00629-3 – volume: 364 start-page: 514 issue: 6 year: 2011 ident: 2023021311515739000_CIT0085 article-title: Everolimus for advanced pancreatic neuroendocrine tumors publication-title: N Engl J Med. doi: 10.1056/NEJMoa1009290 – volume: 55 start-page: 1248 issue: 8 year: 2014 ident: 2023021311515739000_CIT0059 article-title: Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study publication-title: J Nucl Med. doi: 10.2967/jnumed.114.138834 – volume: 384 start-page: 1289 issue: 14 year: 2021 ident: 2023021311515739000_CIT0072 article-title: Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma publication-title: N Engl J Med. doi: 10.1056/NEJMoa2035716 – volume: 11 start-page: 594264 year: 2020 ident: 2023021311515739000_CIT0074 article-title: A durable response with the combination of nivolumab and cabozantinib in a patient with metastatic paraganglioma: a case report and review of the current literature publication-title: Front Endocrinol doi: 10.3389/fendo.2020.594264 – volume: 81 start-page: 642 issue: 5 year: 2014 ident: 2023021311515739000_CIT0048 article-title: Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis publication-title: Clin Endocrinol doi: 10.1111/cen.12542 – volume: 229 start-page: 755 issue: 6 year: 1999 ident: 2023021311515739000_CIT0018 article-title: Clinical experience over 48 years with pheochromocytoma publication-title: Ann Surg. doi: 10.1097/00000658-199906000-00001 – volume: 120 start-page: 1113 issue: 12 year: 2019 ident: 2023021311515739000_CIT0063 article-title: A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial publication-title: Br J Cancer. doi: 10.1038/s41416-019-0474-x – volume: 3 start-page: 25 issue: 1 year: 2018 ident: 2023021311515739000_CIT0097 article-title: External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma publication-title: Adv Radiat Oncol doi: 10.1016/j.adro.2017.11.002 – volume: 26 start-page: 539 issue: 5 year: 2019 ident: 2023021311515739000_CIT0002 article-title: Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-19-0024 – volume: 48 start-page: 1739 issue: 11 year: 2012 ident: 2023021311515739000_CIT0014 article-title: Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2011.07.016 – volume: 91 start-page: 4505 issue: 11 year: 2006 ident: 2023021311515739000_CIT0022 article-title: High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2006-0423 – volume: 51 start-page: 451 issue: 7 year: 2019 ident: 2023021311515739000_CIT0041 article-title: Prognostic factors of malignant pheochromocytoma and paraganglioma: a combined SEER and TCGA databases review publication-title: Horm Metab Res. doi: 10.1055/a-0851-3275 – volume: 5 start-page: 1160 year: 2021 ident: 2023021311515739000_CIT0083 article-title: Novel RET fusion RET-SEPTIN9 predicts response to selective RET inhibition with selpercatinib in malignant pheochromocytoma publication-title: JCO Precis Oncol doi: 10.1200/PO.21.00127 – volume: 20 start-page: 440 issue: 4 year: 2015 ident: 2023021311515739000_CIT0093 article-title: Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis publication-title: Oncologist doi: 10.1634/theoncologist.2014-0328 – volume: 385 start-page: 2036 issue: 22 year: 2021 ident: 2023021311515739000_CIT0076 article-title: Belzutifan for renal cell carcinoma in von Hippel-Lindau disease publication-title: N Engl J Med. doi: 10.1056/NEJMoa2103425 – volume: 27 start-page: 4656 issue: 28 year: 2009 ident: 2023021311515739000_CIT0099 article-title: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group publication-title: J Clin Oncol. doi: 10.1200/JCO.2009.22.8510 – volume: 135 start-page: 2711 issue: 11 year: 2014 ident: 2023021311515739000_CIT0049 article-title: SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma publication-title: Int J Cancer. doi: 10.1002/ijc.28913 – volume: 23 start-page: 34 issue: 1 year: 2012 ident: 2023021311515739000_CIT0061 article-title: Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma publication-title: Endocr Pathol. doi: 10.1007/s12022-011-9189-0 – volume: 24 start-page: 1546 issue: 6 year: 2017 ident: 2023021311515739000_CIT0044 article-title: Surgical treatment of malignant pheochromocytoma and paraganglioma: retrospective case series publication-title: Ann Surg Oncol. doi: 10.1245/s10434-016-5739-5 – volume: 134 start-page: 315 issue: 4 year: 2001 ident: 2023021311515739000_CIT0034 article-title: Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma publication-title: Ann Intern Med. doi: 10.7326/0003-4819-134-4-200102200-00016 – volume: 2015 start-page: 138573 year: 2015 ident: 2023021311515739000_CIT0004 article-title: Profiling of somatic mutations in phaeochromocytoma and paraganglioma by targeted next generation sequencing analysis publication-title: Int J Endocrinol doi: 10.1155/2015/138573 – volume: 29 start-page: 2416 issue: 17 year: 2011 ident: 2023021311515739000_CIT0056 article-title: Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers publication-title: J Clin Oncol. doi: 10.1200/JCO.2010.33.7873 – volume: 57 start-page: 220 issue: 2 year: 2017 ident: 2023021311515739000_CIT0068 article-title: Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma publication-title: Endocrine doi: 10.1007/s12020-017-1359-5 – volume: 127 start-page: 117 issue: 2-03 year: 2018 ident: 2023021311515739000_CIT0030 article-title: Metastatic phaeochromocytoma: spinning towards more promising treatment options publication-title: Exp Clin Endocrinol Diabetes. – volume: 53 start-page: 1481 issue: 9 year: 2012 ident: 2023021311515739000_CIT0058 article-title: Unexpected sensitivity of sst2 antagonists to N-terminal radiometal modifications publication-title: J Nucl Med. doi: 10.2967/jnumed.112.102764 – volume: 35 start-page: E391 issue: 12 year: 2013 ident: 2023021311515739000_CIT0101 article-title: Effects of octreotide therapy in progressive head and neck paragangliomas: case series publication-title: Head Neck doi: 10.1002/hed.23348 – volume: 90 start-page: 2110 issue: 4 year: 2005 ident: 2023021311515739000_CIT0020 article-title: Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2004-1398 – volume: 104 start-page: 1109 issue: 4 year: 2019 ident: 2023021311515739000_CIT0010 article-title: Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2018-02411 – volume: 179 start-page: 740 issue: 5 year: 1974 ident: 2023021311515739000_CIT0016 article-title: Current management of pheochromocytoma publication-title: Ann Surg. doi: 10.1097/00000658-197405000-00029 – volume: 27 start-page: R239 issue: 7 year: 2020 ident: 2023021311515739000_CIT0062 article-title: Antiangiogenic therapies for pheochromocytoma and paraganglioma publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-20-0043 – volume: 27 start-page: 625 issue: 11 year: 2020 ident: 2023021311515739000_CIT0024 article-title: HIF2alpha supports pro-metastatic behavior in pheochromocytomas/paragangliomas publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-20-0205 – volume: 33 start-page: 457 issue: 7_suppl year: 2015 ident: 2023021311515739000_CIT0067 article-title: Phase II clinical trial of axitinib in metastatic pheochromocytomas and paragangliomas (P/PG): preliminary results publication-title: J Clin Oncol. doi: 10.1200/jco.2015.33.7_suppl.457 – volume: 8 start-page: e447 issue: 1 year: 2016 ident: 2023021311515739000_CIT0046 article-title: Complete remission in metastatic pheochromocytoma treated with extensive surgery publication-title: Cureus – volume: 11 issue: 2 year: 2019 ident: 2023021311515739000_CIT0096 article-title: Efficacy and safety of ablative therapy in the treatment of patients with metastatic pheochromocytoma and paraganglioma publication-title: Cancers doi: 10.3390/cancers11020195 – volume: 38 start-page: 1443 issue: 8 year: 2020 ident: 2023021311515739000_CIT0011 article-title: Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension publication-title: J Hypertens. doi: 10.1097/HJH.0000000000002438 – volume: 39 start-page: 1856 issue: 17 year: 2021 ident: 2023021311515739000_CIT0084 article-title: Tipifarnib in head and neck squamous cell carcinoma with HRAS mutations publication-title: J Clin Oncol. doi: 10.1200/JCO.20.02903 – year: 2022 ident: 2023021311515739000_CIT0065 article-title: Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures publication-title: Endocr Relat Cancer. doi: 10.1530/ERC-21-0355 – volume: 6 start-page: bvac044 issue: 5 year: 2022 ident: 2023021311515739000_CIT0069 article-title: Lenvatinib as a therapeutic option in unresectable metastatic pheochromocytoma and paragangliomas publication-title: J Endocr Soc. doi: 10.1210/jendso/bvac044 – volume: 12 year: 2018 ident: 2023021311515739000_CIT0102 article-title: Successful second-line metronomic temozolomide in metastatic paraganglioma: case reports and review of the literature publication-title: Clin Med Insights Oncol doi: 10.1177/1179554918763367 – volume: 105 start-page: 3295 issue: 10 year: 2020 ident: 2023021311515739000_CIT0006 article-title: Sino-European differences in the genetic landscape and clinical presentation of pheochromocytoma and paraganglioma publication-title: J Clin Endocrinol Metab. doi: 10.1210/clinem/dgaa502 – volume: 97 start-page: 4040 issue: 11 year: 2012 ident: 2023021311515739000_CIT0064 article-title: Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2012-2356 |
| SSID | ssj0014453 |
| Score | 2.5554047 |
| SecondaryResourceType | review_article |
| Snippet | Abstract
Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are... Molecular targeted therapy plays an increasingly important role in the treatment of metastatic pheochromocytomas and paragangliomas (PPGLs), which are rare... |
| SourceID | swepub pubmedcentral proquest gale pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2963 |
| SubjectTerms | Adrenal Gland Neoplasms - drug therapy Adrenal Gland Neoplasms - pathology Antimitotic agents Antineoplastic agents Care and treatment Clinical trials CT imaging Denosumab Development and progression Enzyme inhibitors Health aspects Humans Hypoxia-inducible factors Immune checkpoint inhibitors Immunotherapy Inhibitor drugs Medical research Medicine, Experimental Metastases Metastasis metastatic Mini-Review molecular targeted therapy Monoclonal antibodies Paraganglioma Paraganglioma - drug therapy Paraganglioma - pathology PET imaging Pheochromocytoma Pheochromocytoma - drug therapy Pheochromocytoma - pathology Randomized Controlled Trials as Topic Reviews Sunitinib - therapeutic use Temozolomide Temozolomide - therapeutic use Tumors Tyrosine Vaccination Zoledronic acid |
| Title | Targeted Therapies in Pheochromocytoma and Paraganglioma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35973976 https://www.proquest.com/docview/3164495793 https://www.proquest.com/docview/2703417292 https://pubmed.ncbi.nlm.nih.gov/PMC9923802 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-497517 |
| Volume | 107 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkRAXxJtAQQGBOKDsNrEdx8cuUFYrLeLQRb1ZtuM-UDdBbSoBv57xo2lDF7FwiarEtRPP54k_Z-YzQq8yqznumCqQj4QwqhKJFUlMCXNvp6HvMrzPPuUn5-R0TMfb3BOXXdKoQ_3z0ryS_7EqnAO72izZf7BsWymcgN9gXziCheF4NRu7MG6YMo5cFtXcBVe9_TwztZ7ZMDv9o6kvpE8IkEs5lTZntw6e-OsWJzvyEW2mpKnKGjxKtdVoujANIGax0Rx0q_DBU9gF-GXYiNt90VjWPtfstIYZalv-2KyBTC_C_ppDs5h_38b_wNs6rMYOVjPrqo4Pd5ckgM2m7ZKE96Kc0ISlPvC2dbN-d9sNntJdr8m9k9tz58BHwQb2yQ2MjmE5lZr4HVsuEcl-P_8yEPVyKtZrQTijKbuObmSMua_3H8dt5A9QyCBOaqNTWDZ2gQfhjoOup01s8s0ehUY785bw9u6kRO4wk_0A244MrZu6jO6g24FzxAMPoLvomqnuoZtnIariPio2OIpbHMXzKv4dRzGAIO7g6AE6H34YvTtJwo4aiaZF1iSpUaowmClNyonKGWdcMZ3RoqAFz6mhJTW81DKDcT0huTG6zycGKzkxFHOJ8UN0UNWVeYxig1PNjJTKTKy-UaGULotSckX6mJU0j1Cy6S-hg9y83fVkISzthP4Vvn9F6N8IvWnLf_NCK38uabtfWKRAjVqGRBK4L6tlJgaMAQlmJCcR6nVKgufUncsvwYB_ba23sa8Io3ElcAo0wn7gxhF60V621duQxcrU65XI4F1KgB7wLEKPPBzapjDQeEsEIsQ6QGkLWDx3r1TzmRN_58DIij7U-dpDqvOX_SHw5IrlnqJb25HcQwfNcm2ewXS7Uc_d4PkF-incIA |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+Therapies+in+Pheochromocytoma+and+Paraganglioma&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Wang%2C+Katharina&rft.au=Crona%2C+Joakim&rft.au=Beuschlein%2C+Felix&rft.au=Grossman%2C+Ashley+B.&rft.date=2022-11-01&rft.issn=1945-7197&rft.volume=107&rft.issue=11&rft.spage=2963&rft_id=info:doi/10.1210%2Fclinem%2Fdgac471&rft.externalDocID=oai_DiVA_org_uu_497517 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |